Extended Efficacy of Once-Daily Atomoxetine in ADHD
نویسندگان
چکیده
منابع مشابه
Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Methylphenidate, a psychostimulant, is first choice treatment for Attention Deficit Hyperactivity Disorder (ADHD)(Dopfner et al. 2002). Unfortunately, it has many adverse side effects, especially depression and appetite loss, which limits its dosage. There are only a few studies investigating the effect of a combination of Methylphenidate and other psychoactive substances, especially antidepres...
متن کاملOnce-daily treatment of ADHD with guanfacine: patient implications
The standard of care for treating ADHD is to use a psychostimulant as the first line agent. Recent medical literature reports that approximately 70%-90% of patients with ADHD received some benefit from a stimulant medication. Even though psychostimulants have a high rate of efficacy, an estimated 30%-50% of children and adults may discontinue psychostimulants secondary to adverse effects or ina...
متن کاملAtomoxetine and tics in ADHD.
Atomoxetine is a nonstimulant medication shown to be efficacious in the treatment of attention-deficit/hyperactivity disorder (ADHD). There have been no reports to date of tics being precipitated or exacerbated by atomoxetine. We report four patients with ADHD who had developed tics on stimulants and in whom tics reappeared or were exacerbated on atomoxetine. Moreover, the tics resolved or abat...
متن کاملOcular hypotensive efficacy and safety of once daily carteolol alginate.
BACKGROUND/AIM Carteolol is a beta adrenoceptor antagonist used topically to reduce intraocular pressure, typically twice daily. In an effort to provide a once daily dosing regimen, carteolol was formulated with 1% alginic acid. The objective of this study was to evaluate the efficacy and safety of carteolol alginate solution in comparison with standard carteolol solution. METHODS This was a ...
متن کاملPotential benefit of dolutegravir once daily: efficacy and safety
The viral integrase enzyme has recently emerged as a primary alternative target to block HIV-1 replication, and integrase inhibitors are considered a pivotal new class of antiretroviral drugs. Dolutegravir is an investigational next-generation integrase inhibitor showing some novel and intriguing characteristics, ie, it has a favorable pharmacokinetic profile with a prolonged intracellular half...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Neurology Briefs
سال: 2004
ISSN: 2166-6482,1043-3155
DOI: 10.15844/pedneurbriefs-18-7-1